Drug
Gadoterate Meglumine
Gadoterate Meglumine: highest development phase Post-Market, developed by Guerbet. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Guerbet
Trials
| Drug | Phase | Indication |
|---|---|---|
| Gadoterate meglumine NCT01806740 | Post-Market | Hepatocellular Carcinoma |
| Gadoterate meglumine (Dotarem) NCT00845702 | Phase 3 | Renal Artery Stenosis |
Latest
No recent events.
Follow Gadoterate Meglumine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.